An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Launched by XENTRIA, INC. · Dec 12, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Participants are eligible to be included in the study if the following criteria apply:
- • Completion of XTMAB-16-201 study: completion of Week 12 (Part A) or Week 24 (Part B) assessments.
- • Participants from XTMAB-16-201 Part A and Part B should be on a stable steroid dose for at least 2 weeks prior to informed consent/Day 1 of XTMAB-16-202 (Day 1 should occur at the next scheduled dosing visit on the assigned dose frequency cohort of XTMAB 16 201 ± 2 weeks).
- Exclusion Criteria:
- Participants are excluded from the study if any of the following criteria apply:
- • Evidence of treatment-related AEs requiring treatment discontinuation per XTMAB-16-201 protocol observed in XTMAB-16-201 study.
- • Evidence of treatment failure observed in XTMAB-16-201 study per protocol definition.
About Xentria, Inc.
Xentria, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients with unmet medical needs. Focused on advancing treatments primarily in the areas of autoimmune diseases and inflammatory conditions, Xentria leverages cutting-edge science and technology to drive its clinical programs. The company's commitment to research and development is underscored by a robust pipeline of drug candidates aimed at improving patient outcomes and enhancing quality of life. With a patient-centric approach, Xentria collaborates with healthcare professionals and stakeholders to ensure the highest standards of safety and efficacy in its clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norwich, , United Kingdom
London, England, United Kingdom
Greenville, North Carolina, United States
Chicago, Illinois, United States
Philadelphia, Pennsylvania, United States
Denver, Colorado, United States
Perth, Scotland, United Kingdom
Norwich, England, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported